Brain Tumour Research publications
Learn more about the publications our research has featured in
Selected publications
Full listing of Professor C Oliver Hanemann’s publications available from and via
2021
Sofela AA, Hilton DA, Ammoun S, Baiz D, Adams CL, Ercolano E, Jenkinson MD, Kurian KM, Teo M, Whitfield PC, Sahm F, Hanemann CO (2021) 'Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningioma' International Journal of Molecular Science. Jan 8;22(2):560.
Barros CS, and Bossing T (2021) 'Microtubules Disruption upon Damage in the CNS Triggers Mitosis via Activation of TNFa Signalling', Cell Reports. Jul 6;36(1):109325.
Bettegowda C, Upadhayaya M, Evans DG, Kim A, Mathios D and Hanemann CO for the REiNS International Collaboration (2021) 'Genotype-Phenotype Correlations in Neurofibromatosis and their Potential Clinical Use', Neurology, Aug 17;97(7 Suppl 1):S91-S98.
Maze EA, Agit B, Reeves S, Hilton DA, Parkinson DB, Laraba L, Ercolano E, Kurian KM, Hanemann CO, Belshaw RD, Ammoun S (2021) 'Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Anti-retroviral Drugs in Merlin-negative Schwannoma and Meningioma' Cancer Research. Dec 1:canres.3857.2020.
Plotkin SR, Messiaen L, Legius E, Pancza P, Avery RA, Blakeley J, Babovic-Vuksanovic D, Ferner R, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Hanemann CO, Kalamarides M, Kehrer-Sawatzki H, Korf BR, Mautner VF, MacCollin M, Papi L, Rauen KA, Riccardi V, Schorry E, Smith M, Stemmer-Rachamimov A, Stevenson DA, Ullrich NJ, Viskochi D, Wimmer K, Yohay K, International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC), Huson SM, Wolkenstein P, Evans DG, MD (in press) 'Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation' Genetics in Medicine, IF 8.82
2020
Dunn J, Lenis VP, Hilton DA, Warta R, Herold-Mende C, Hanemann CO, Futschik ME. (2020) 'Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma' Cancers (Basel).12(11):E3270.
Adams CL, Ercolano E, Ferluga S, Sofela A, Dave F, Negroni C, Kurian KM, Hilton DAand Hanemann CO. (2020) ‘A rapid robust method for subgrouping non-NF2 meningiomas according to genotype and detection of lower levels of M2 macrophages in AKT1 E17K mutated tumours’ International Journal of Molecular Sciences21 (4), 1273
Adams CL, Ercolano E, Ferluga S, Sofela A, Dave F, Negroni C, Kurian KM, Hilton DAand Hanemann CO. (2020) ‘A rapid robust method for subgrouping non-NF2 meningiomas according to genotype and detection of lower levels of M2 macrophages in AKT1 E17K mutated tumours’ International Journal of Molecular Sciences21 (4), 1273
Negroni C, Hilton DA, Ercolano E, Adams CL, J, Kurian KM, Baiz Dand Hanemann CO. (2020) 'The transcription factor GATA-4 is overexpressed in malignant meningioma regulating miR-497~195 expression levels and proliferation' EBioMed 59, 102941
Palomo-Irigoyen M, Pérez-Andrés E, Iruarrizaga-Lejarreta M, Varela-Rey M, Barreira-Manrique A, Tamayo-Caro M, Beitia N, Medrano D, Lozano JJ, Okawa S, LavÃn JL, MartÃn-MartÃn N, Sutherland JD, Fernandez-Ramos D, Guitiérez de Juan V, González-Lopez M, MacÃas-Cámara N, Mosén-Ansorena D, Laraba L,Hanemann CO, Ercolano E, Parkinson DB, Schultz CW, Araúzo-Bravo MJ, Ascensión AM, Gerovska D, Iribar H, Izeta A, Pytel P, Krastel P, Provenzani A, Seneci P, Carrasco RD, Carracedo A, Del Sol A, Martinez-Chantar ML, Barrio R, Serra E, Lazaro C, Flanagan AM, Gorospe M, Ratner N, Carracedo A, Aransay AM, Woodhoo A. (2020) ‘HuR/ELAVL1 drives malignant peripheral nerve sheath tumour growth and metastasis’ Journal of Clinical Investigation 130 (7), 3848-3864
Rimmer JL,Ercolano E, Baiz D, Makhija M, Berger A, Sells T, Stroud S, Hilton DA, Adams CL, Hanemann CO.(2020) ‘The potential of MLN3651 in combination with selumetinib as a treatment for Merlin-deficient meningioma’ Cancers (Basel)12 (7), 1744
2019
Ammoun S, Evans G, Hilton DA, Streeter A, Hayward C, Hanemann CO(2019) ‘Phase 0 trial investigating the intra-tumoural concentration and activity of Sorafenib in Neurofibromatosis type’ Journal of Neurology, Neurosurgery and Psychiatry90, 1184-1187
Brastianos PK, Galanis E, Butowski N, Chan JW, Dunn IF, Goldbrunner R, Herold-Mende C, Ippen FM, Mawrin C, McDermott MW, Sloan A, Snyder J, Tabatabai G, Tatagiba M, Tonn JC, Wen PY, Aldape K, Nassiri F, Zadeh G, Jenkinson MD, Raleigh DR; International Consortium on Meningiomas. (2019) ‘Advances in multidisciplinary therapy for meningiomas.’ Neuro Oncology21 (Suppl1) i18-i31
Dong N, Shi X, Wang S, Gao Y, Huang Z, Xie Q, Li Y, Deng H, Wu Y, Li M, Li JL. (2019) ‘M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma.’ Br J Cancer121 (1), 22-33
Dun XP, Carr L, Woodley PK, Barry RW, Drake LK, Mindos T, Roberts SL, Lloyd AC, Parkinson DB. (2019) ‘Macrophage-Derived Slit3 Controls Cell Migration and Axon Pathfinding in the Peripheral Nerve Bridge.’ Cell Reports26 (6), 1458-1472.
Edge R, Mills R, Tennant A, Diggle PJ, Young CA, TONiC Study Group (2019) 'Do pain, anxiety and depression influence quality of life for people with amyotrophic lateral sclerosis/motor neuron disease? A national study reconciling previous conflicting literature' Journal of Neurology267, (3) pp 607-615.
Ferluga S, Baiz D, Hilton DA, Adams CL, Ercolano E, Dunn J, Bassiri K, Kurian KM and Hanemann CO(2019) ‘Constitutive activation of the EGFR-STAT1 axis increases proliferation of meningioma tumor cells’ Neuro Oncology Advances2 (1)
Gil-Ranedo, J., Gonzaga, E., Jaworek, K., Berger, C., Bossing, T. and Barros C.S (2019) ‘STRIPAK members orchestrate Hippo and Insulin Receptor Signalling to promote neural stem cell reactivation’ Cell Reports27 (10) 2921-2933
Halliday D, Emmanouil B, Vassallo G, Lascelles K, Nicholson J, Chandratre S, Anand G, Wasik M, Pretorius P & Evans DG (2019) 'Trends in phenotype in the English paediatric neurofibromatosis type 2 cohort stratified by genetic severity' Clinical Genetics: an international journal of genetics and molecular medicine96, (2) pp 151-162.
Hanemann CO, Ammoun S, Evans G, Hilton DA, Streeter A & Hayward C (2019) 'Phase 0 trial investigating the intra-tumoural concentration and activity of Sorafenib in Neurofibromatosis type 2' Journal of Neurology, Neurosurgery and Psychiatry.
Huang RY, Bi WL, Griffith B, Kaufmann TJ, la Fougère C, Schmidt NO, Tonn JC, Vogelbaum MA, Wen PY, Aldape K, Nassiri F, Zadeh G, Dunn IF; International Consortium on Meningiomas (2019) ‘Imaging and diagnostic advances for intracranial meningioma.’ Neuro Oncology21 (Suppl1) i44-i61
Mills SJ, Radon MR, Baird RD, Hanemann CO, Keatley D, Lewis J, Pollock J, Sanghera P, Santarius T & Whitfield G (2019) 'Utilization of volumetric magnetic resonance imaging for baseline and surveillance imaging in Neuro-oncology' The British Journal of Radiologypp 20190059-20190059.
Nassiri F, Mamatjan Y, Suppiah S, Badhiwala JH, Mansouri S, Karimi S, Saarela O, Poisson L, Gepfner-Tuma I, Schittenhelm J, Ng HK, Noushmehr H, Harter P, Baumgarten P, Weller M, Preusser M, Herold-Mende C, Tatagiba M, Tabatabai G, Sahm F, von Deimling A, International Consortium on Meningiomas, Zadeh G, Aldape KD. (2019) ‘DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management’ Neuro Oncology21 (7), 901-910
Nassiri F, Price B, Shehab A, Au K, Cusimano MD, Jenkinson MD, Jungk C, Mansouri A, Santarius T, Suppiah S, Teng KX, Toor GS, Zadeh G, Walbert T, Drummond KJ, International Consortium on Meningiomas (2019) ‘Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life.’ Neuro Oncology21 (Suppl1), i32-i43
Shefner JM, Cudkowicz ME, Hardiman O, Cockroft BM, Lee JH, Malik FI, Meng L, Rudnicki SA, Wolff AA & Andrews JA (2019) 'A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis' Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration20, (7-8) pp 584-594.
2019 (Cont.)
Suppiah S, Nassiri F, Bi WL, Dunn IF, Hanemann CO, Horbinski CM, Hashizume R, James CD, Mawrin C & Noushmehr H (2019) 'Molecular and translational advances in meningiomas' Neuro-Oncology21, (Supplement_1) pp i4-i17.
Young CA, Ealing J, McDermott C, Williams T, Al-Chalabi A, Majeed T, Burke G, Pinto A, Dick D & Talbot K (2019) 'The relationships between symptoms, disability, perceived health and quality of life in amyotrophic lateral sclerosis/motor neuron disease' Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration20, (5-6) pp 317-327.
2018
Collord G, Tarpey P, Kurbatova N, Martincorena I, Moran S, Castro M, Nagy T, Bignell G, Maura F & Young MD (2018) 'An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures' Scientific Reports8, (1) pp 13537-13537
Dunn J,Ferluga S, Sharma V, Futschik M, Hilton DA, Adams CL, Lasonder E & Hanemann CO(2018) 'Proteomic analysis discovers the differential expression of novel proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and deregulation of RNA metabolism' EBioMedicine
Hanemann CO, Emmanouil B, Houston R, May A, Ramsden JD, Halliday D, Parry A & Mackeith S (2018) 'Progression of Hearing Loss in Neurofibromatosis Type 2 According to Genetic Severity' The Laryngoscope 129 (4), 974-980
Milinis K, Tennant A, Mills RJ, Al-Chalabi A, Burke G, Dick DJ, Ealing J, Hanemann CO, Harrower T & McDermott CJ (2018) 'Development and validation of Spasticity Index-Amyotrophic Lateral Sclerosis' Acta Neurologica Scandinavica
Raghu S.V, Mohammad F, Chua J.Y, Lam J.S.W, Loberas M, Sahani S, Barros C.S, Claridge-Chang A. (2018) ‘A zinc-finger fusion protein refines Gal4-defined neural circuits.’ Molecular Brain11, (46)
2017
Bassiri K, Ferluga S, Sharma V, Lasonder E, Hanemann CO (2017) ‘Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target’ EBiodMedicine16, 76-86.
Button RW, Roberts SL, Willis TL, Hanemann CO, Luo S (2017) ‘Accumulation of autophagosomes confers cytotoxicity’ Journal of Biological Chemistry292, 13599-13614.
Cooper J, Zhou L, Ojeda V, Moulick K, de Stanchina E, Poirier JT, Rudin CM, Hanemann CO, Giancotti FG (2017) ‘Preclinical efficacy of combined inhibition of NEDD8-activating enzyme and mTOR in NF2-mutant tumours’ Molecular Cancer Therapeutics16, (8) 1693-1704.
Mindos T, Dun XP, North K, Doddrell RD, Schulz A, Edwards P, Russell J, Gray B, Roberts SL, Shivane A, Mortimer G, Pirie M, Zhang N, Pan D, Morrison H, Parkinson DB(2017) ‘Merlin controls the repair capacity of Schwann cells after injury by regulating Hippo/YAP activity’ J Cell Biol.216 (2) 495-510.
Oon CE, Bridges E, Sheldon H, Sainson RCA, Jubb A, Turley H, Leek R, Buffa F, Harris AL, Li JL(2017) ‘Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth’ Oncotarget8, (25) 40115-40131.
Provenzano L, Ryan Y, Hilton DA, Lyons-Rimmer J, Dave F, Maze EA, Adams CL, Rigby-Jones R, Ammoun S, Hanemann CO(2017) ‘Cellular prion protein (PrPC) in the development of Merlin-deficient tumours’ Oncogene36, (44) 6132-6142.
Roberts SL, Dun XP, Doddrell RDS, Mindos T, Drake LK, Onaitis MW, Florio F, Quattrini A, Lloyd AC, D'Antonio M, Parkinson DB. (2017) ‘Sox2 expression in Schwann cells inhibits myelination in vivo and induces influx of macrophages to the nerve’ Development3114-3125.
Stepanova DS, Semenova G, Kuo YM, Andrews AJ, Ammoun S, Hanemann CO, Chernoff J (2017) ‘An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis’ Cancer Res77, (18) 5026-5038.
2016
Ding R, Weynans K, Bossing T, Barros CS, Berger C. (2016) ‘The Hippo signalling pathway maintains quiescence in Drosophila neural stem cells’ Nature Communications 7, 10510.
Hanemann CO, Blakeley JO, Nunes FP, Robertson K, Stemmer-Rachamimov A, Mautner V, Kurtz A, Ferguson M, Widemann BC, Evans DG, Ferner R, Carroll SL, Korf B, Wolkenstein P, Knight P, Plotkin SR (2016) ‘Current status and recommendations for biomarkers and biobanking in neurofibromatosis’ Neurology87, (7 Supplement 1), S40-S48.
Hilton DA, Shivane A, Kirk L, Bassiri K, Enki DG, Hanemann CO.(2016) ‘Activation of multiple growth factor signalling pathways is frequent in meningiomas.’ Neuropathology36, (3) 250-261.
McIntyre, A., Hulikova, A., Ledaki, I., Snell, C., Singleton, D., Steers, G., Seden, P., Jones, D., Bridges, E., Wigfield, S., Li, J.L., Russell, A., Swietach, P. and Harris, A.L. (2016) ‘Disrupting hypoxia-induced bicarbonate transport acidifies tumor cells and suppresses tumor growth’ Cancer Research 76, (13) 3744-3755.
Schulz A, Büttner R, Hagel C, Baader SL, Kluwe L, Salamon J, Mautner VF, Mindos T, Parkinson DB, Gehlhausen JR, Clapp DW, Morrison H (2016) ‘The importance of nerve microenvironment for schwannoma development’ Acta Neuropathol.2016 Aug;132(2):289-307.
Zhou L, Lyons-Rimmer J, Ammoun S, Müller J, Lasonder E, Sharma V, Ercolano E, Hilton D, Taiwo I, Barczyk M, Hanemann CO(2016) ‘The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors’ Oncogene35, (26) 3443-3453.
2015
McDermott CJ, Shaw PJ, Cooper CL, Dixon S, Baird WO, Bradburn MJ, Fitzgerald P, Maguire C, Williams T, Baudouin SV, Karat D, Talbot K, Stradling J, Maynard N, Turner M, Bianchi S, Ackroyd R, Bourke SC, Ealing J, Bentley A, Galloway S, Orrell RW, Wedzicha W, Elliot M, Hughes P, Hanemann CO(2015) ‘Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial’ Lancet Neurol14, (9) 883-892.
McDermott CJ, Shaw PJ, Stavroulakis T, Walters SJ, Al-Chalabi A, Chandran S, Crawley F, Dick D, Donaghy C, Eames P, Fish M, Gent C, Gorrie G, Hamdalla H, Hanemann CO, Johnson M, Majeed T, Malaspina A, Morrison K, Orrell R, Pinto A, Radunovic A, Roberts M, Talbot K, Turner MR, Williams T, Young C (2015) ‘Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study’ Lancet Neurol 14, (9) 702-707.
Ammoun S, Schmid MC, Zhou L, Hilton DA, Barczyk M, Hanemann CO(2015) ‘The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours’ Mol Oncol9, (1) 236-248.
2014
Li W, Cooper J, Zhou L, Yang C, Erdjument-Bromage H, Zagzag D, Snuderl M, Ladanyi M, Hanemann CO, Zhou P, Karajannis MA, Giancotti FG (2014) ‘Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus’ Cancer Cell 26, (1) 48-60.
Ammoun S, Provenzano L, Zhou L, Barczyk M, Evans K, Hilton DA, Hafizi S, Hanemann CO (2014) ‘Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival’ Oncogene 33, (3) 336-346.
2013
Plotkin SR, Blakeley JO, Dombi E, Fisher MJ, Hanemann CO, Walsh KS, Wolters PL, Widemann BC (2013) ‘Achieving consensus for clinical trials The REiNS International Collaboration’ Neurology 81, (21) S1-S5.
Schulz A, Baader SL, Niwa-Kawakita M, Jung MJ, Bauer R, Garcia C, Zoch A, Schacke S, Hagel C, Mautner VF, Hanemann CO, Dun XP, Parkinson DB, Weis J, Schröder JM, Gutmann DH, Giovannini M, Morrison H (2013) ‘Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy’ Nature Neurosci 16, (4) 426-U86.
Doddrell RD, Dun XP, Shivane A, Feltri ML, Wrabetz L, Wegner M, Sock E, Hanemann CO, Parkinson DB (2013) ‘Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells’ Brain 136, (Pt 2) 549-563.
2012
Sher I, Hanemann CO, Karplus PA, Bretscher A (2012) ‘The tumor suppressor merlin controls growth in its open state, and phosphorylation converts it to a less-active more-closed state’ Dev Cell 22, (4) 703-705.
Ammoun S, Schmid MC, Zhou L, Ristic N, Ercolano E, Hilton DA, Perks CM, Hanemann CO (2012) ‘Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival’ Oncogene 31, (13) 1710-1722.
2011
Ammoun S, Schmid MC, Triner J, Manley P, Hanemann CO (2011) ‘Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2’ Neuro Oncol 13, (7) 759-766.
Ammoun S, Hanemann CO (2011) ‘Emerging therapeutic targets in schwannomas and other merlin-deficient tumors’ Nat Rev Neurol 7, (7) 392-9.
2010
Ammoun S, Cunliffe CH, Allen JC, Chiriboga L, Giancotti FG, Zagzag D, Hanemann CO, Karajannis MA (2010) ‘ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma’ Neuro Oncol 8, (12) 834-43.
Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini M, Hanemann CO, Long SB, Erdjument-Bromage H, Zhou P, Tempst P, Giancotti FG (2010) ‘Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4(DCAF1) in the Nucleus’ Cell 140, (4) 477-490.
Pre-2010
Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO (2008) ‘Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma’ Cancer Res 68, (13) 5236-5245.
Flaiz C, Utermark T, Parkinson DB, Poetsch A, Hanemann CO (2008) ‘Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells’ Glia 56, (5) 506-515.
Hanemann CO (2008) ‘Magic but treatable? Tumours due to loss of Merlin’ Brain 131, 606-615.
Hanemann CO, Diebold R, Kaufmann D (2007) ‘Role of NF2 Haploinsufficiency in NF2-associated Polyneuropathy’ Brain Pathol 17, (4) 371-376.